Company: TAK
Filing Date: 2025-07-30
Form Type: 6-K
Source: 0001395064-25-000120
Chunk: 13

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-07-30
Form: 6-K
Chunk 13
---
.0% CER).

* Takeda’s Growth and Launch Products

GI: ENTYVIO, EOHILIA

Rare Diseases: TAKHZYRO, LIVTENCITY, ADZYNMA

PDT: Immunoglobulin products including GAMMAGARD LIQUID/KIOVIG, HYQVIA, and CUVITRU,

Albumin products including HUMAN ALBUMIN and FLEXBUMIN

Oncology: ALUNBRIG, FRUZAQLA

Vaccines: QDENGA

#### Core Operating Profit
Core Operating Profit was JPY 321.8 billion (JPY -60.4 billion and -15.8% AER, -11.9% CER ) . The components of Core Operating Profit are as below:

|                                                          |     |            |     |         |     |           |     |         |     |          |     |        |     |       |   |     |     |       | Billion JPY or percentage |
|                                                          |     | FY2024 Q1  |     |         |     | FY2025 Q1 |     |         |     | AER      |     |        |     |       |   | CER |     |       |                           |
|                                                          |     | JPY Change |     |         |     | % Change  |     |         |     | % Change |     |        |     |       |   |     |     |       |                           |
| Core revenue                                             |     |            |     | 1,208.0 |     |           |     | 1,106.7 |     |          |     | -101.3 |     |  -8.4 | % |     |     |  -3.7 | %                         |
| Core cost of sales                                       |     |            |     |  -387.1 |     |           |     |  -384.9 |     |          |     |    2.2 |     |  -0.6 | % |     |     |   4.4 | %                         |
| Core selling, general and administrative (SG&A) expenses |     |            |     |  -270.2 |     |           |     |  -256.0 |     |          |     |   14.1 |     |  -5.2 | % |     |     |  -0.0 |